Lead Product(s) : Dutasteride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2024
Lead Product(s) : Dutasteride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dutasteride,Tadalafil
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Will Dongkook Pharm Present New Combo Therapy for BPH?
Details : DKF-313 is a combination of dutasteride (5α-reductase inhibitor) and tadalafil (PDE5 inhibitor). It is being evaluated in phase 3 clinical trials for the treatment of benign prostatic hyperplasia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : Dutasteride,Tadalafil
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dutasteride
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Yuyu Pharma Plans to Enter the U.S. and European Markets for Hair Loss Treatment
Details : Dutasteride inhibits both Type I and Type II 5-alpha reductase which act to transform testosterone, a male hormone, into a DHT hormone. In scientific studies, excess DHT is understood to be the cause of hair loss.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2022
Lead Product(s) : Dutasteride
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dutasteride,Azithromycin,Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Applied Biology
Deal Size : Undisclosed
Deal Type : Collaboration
Applied Biology in Collaboration with Corpometria Institute to Launch ANDROCOV TRIAL for COVID-19
Details : ANDROCOV trial is for a Generic Anti-androgen as a Treatment For COVID-19 taking Dutasteride, Ivermectin, Azithromycin and Proxalutamide under combination.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 09, 2020
Lead Product(s) : Dutasteride,Azithromycin,Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Applied Biology
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Dutasteride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : National Institute on Alcohol Abuse and Alcoholism
Deal Size : Inapplicable
Deal Type : Inapplicable
Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2019
Lead Product(s) : Dutasteride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : National Institute on Alcohol Abuse and Alcoholism
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dutasteride
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2016
Lead Product(s) : Dutasteride
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dutasteride
Therapeutic Area : Urology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2015
Lead Product(s) : Dutasteride
Therapeutic Area : Urology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dutasteride
Therapeutic Area : Urology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2015
Lead Product(s) : Dutasteride
Therapeutic Area : Urology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dutasteride
Therapeutic Area : Urology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2014
Lead Product(s) : Dutasteride
Therapeutic Area : Urology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dutasteride
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2014
Lead Product(s) : Dutasteride
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
